for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Top News

U.S. should not wait too long on AstraZeneca vaccine, Oxford's Hill says

FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed AstraZeneca logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) - Jenner Institute Director Adrian Hill, who oversees the Oxford-AstraZeneca COVID-19 vaccine research and development, said a vaccine would not be available in the United States until “the middle of next year” if regulators wait for the end of their vaccine trial.

“I would hope that the (Food and Drug Administration) would look at the data set on this vaccine, including all of the available data in January. To wait for the end of the trial would be the middle of next year,” Hill said in remarks released by NBC. “That’s too late to take the value of this vaccine, which is effective, available at large scale and easily deployed.”

Dr. Larry Corey, a top U.S. scientist overseeing COVID-19 vaccine trials, last week said the large U.S. AstraZeneca study may determine how effective the vaccine is, after perplexing results from other trials by the company and partner Oxford.

Moncef Slaoui, chief adviser for the U.S. Operation Warp Speed vaccine program, said last week that U.S. trial data and potentially a request for U.S. emergency use authorization by AstraZeneca could come in late January.

Reporting by Kanishka Singh in Bengaluru; Editing by Peter Henderson and Leslie Adler

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up